Irena Dujmovic Basuroski, MD
Neurology · Chapel Hill, NCNPI 1932637568
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. Novartis accounts for 88.4% of it on its own, with 2 other manufacturers making up the rest. 2024 is the largest year on record at $599, more than ten times the $19 reported in 2022. That places this record below the midpoint for neurology clinicians in NC, where the typical reported total is $688.
Across 6 payments — averaging $112.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$599
- Biogen$60
- Amgen$19
Across 69 payments — averaging $17,994 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$779K
- Biogen$201K
- Bristol Myers Squibb$122K
- AstraZeneca$99K
- EMD Serono, Inc.$40K
- Ares Trading SA$680
What the payments were for
- Travel & lodging$27240%
- Food & beverage$34651%
- Education$609%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$678 in reported general payments places this provider in the 45th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 51 | $535,282 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 25 | $159,701 |
| VumerityDiroximel Fumarate | 12 | $100,918 |
| Dalfampridine ErDalfampridine | 24 | $11,293 |
| MyrbetriqMirabegron | 14 | $6,293 |
| Gabapentin | 170 | $5,018 |
| Carbamazepine ErCarbamazepine | 36 | $4,774 |
| FingolimodFingolimod Hcl | 12 | $3,685 |
| Dimethyl Fumarate | 16 | $2,557 |
| Baclofen | 90 | $1,741 |
| Lacosamide | 17 | $1,547 |
| Trospium Chloride | 14 | $991 |
| AmantadineAmantadine Hcl | 30 | $866 |
| Mycophenolate Mofetil | 13 | $861 |
| Solifenacin Succinate | 30 | $801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $60 | $100,91812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 566 neurology providers in North Carolina.
Other neurology in Chapel Hill
- James HowardChapel Hill$294K
- O'Neill D'cruzChapel Hill$57K
- Jill ConwayCharlotte$1M
- Matthew CarraroCharlotte$695K
- Richard SaterGreensboro$682K
- Sara SaccoMatthews$651K
- Megan DonnellyCharlotte$601K
- Kevin KahnDurham$587K
- Sanjay IyerCharlotte$581K
- Mark SkeenDurham$562K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.